DYAI · Dyadic International Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.11M | - | $1.16M | $966.6K | $393.6K | - | $1.96M | $385.9K | $334.6K | - |
| Cost of Revenue | $791.8K | - | $1.02M | - | - | - | $395.9K | $302.0K | $144.0K | - |
| Gross Profit | $319.1K | - | $140.6K | - | - | - | $1.56M | $83.9K | $190.7K | - |
| R&D | $476.1K | - | $571.9K | $629.4K | $495.0K | - | $460.2K | $515.6K | $522.7K | - |
| SG&A | $1.76M | - | $1.48M | $1.44M | $1.60M | - | $1.30M | $1.61M | $1.79M | - |
| Total Operating Expenses | $3.01M | - | $3.09M | $2.70M | $2.40M | - | $2.16M | $2.43M | $2.46M | - |
| D&A | - | - | - | - | - | - | - | - | - | - |
| Operating Income | ($1.90M) | - | ($1.93M) | ($1.73M) | ($2.00M) | - | ($202.6K) | ($2.04M) | ($2.13M) | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | $0 | - | - | - | - | - | - | - | - | - |
| Net Income | ($1.95M) | - | ($1.98M) | ($1.79M) | ($2.03M) | - | ($203.5K) | ($2.05M) | ($2.01M) | - |
| EPS - Basic | ($0.05) | - | ($0.06) | ($0.06) | ($0.07) | - | ($0.01) | ($0.07) | ($0.07) | - |
| EPS - Diluted | ($0.07) | - | ($0.06) | ($0.07) | - | - | - | - | - | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $4.25M | $4.62M | $5.83M | $2.14M | $5.06M | $6.51M | $5.92M | $6.13M | $10.57M | $6.52M |
| Accounts Receivable | $996.5K | $1.09M | $916.6K | $715.3K | $221.7K | $237.0K | $352.9K | $249.8K | $246.1K | $466.2K |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $1.06M | $852.0K | $1.21M | $738.8K | $448.4K | $482.3K | $561.8K | $432.5K | $661.2K | $656.4K |
| Current Assets | $7.70M | $9.90M | $11.55M | $7.41M | $7.81M | $9.83M | $10.69M | $10.50M | $12.54M | $8.07M |
| Total Assets | $7.81M | $9.95M | $11.67M | $8.14M | $7.89M | $9.93M | $10.81M | $10.63M | $12.68M | $8.22M |
| Current Liabilities | $3.18M | $3.69M | $4.05M | $3.66M | $1.96M | $2.45M | $2.08M | $1.95M | $2.26M | $2.25M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $8.22M | $8.71M | $9.07M | $8.67M | $6.97M | $7.46M | $7.39M | $7.46M | $8.17M | $2.34M |
| Stockholders' Equity | ($407.7K) | $1.23M | $2.61M | ($529.7K) | $923.6K | $2.47M | $3.41M | $3.17M | $4.52M | $5.88M |
| Retained Earnings | ($95.41M) | ($93.45M) | ($91.88M) | ($89.91M) | ($88.11M) | ($86.09M) | ($84.54M) | ($84.33M) | ($82.29M) | ($80.28M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($1.96M) | - | - | - | ($1.95M) | - | - | - | ($1.11M) | - |
| Investing Cash Flow | $1.27M | - | - | - | $482.1K | - | - | - | ($654.9K) | - |
| Financing Cash Flow | - | - | - | - | $24.2K | - | - | - | $5.82M | - |
| CapEx | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 28.7% | - | 12.1% | - | - | - | 79.8% | 21.8% | 57.0% | - |
| Operating margin | -171.3% | - | -165.3% | -178.9% | -508.8% | - | -10.4% | -529.3% | -635.2% | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | -175.9% | - | -169.7% | -185.6% | -515.2% | - | -10.4% | -530.0% | -600.6% | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | 42.9% | - | 49.1% | 65.1% | 125.8% | - | 23.5% | 133.6% | 156.2% | - |
| SG&A / Revenue | 158.0% | - | 127.2% | 148.6% | 405.6% | - | 66.3% | 416.6% | 534.5% | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -25.0% | - | -16.9% | -22.0% | -25.7% | - | -1.9% | -19.2% | -15.8% | - |
| Return on equity | 479.4% | - | -75.8% | 338.6% | -219.5% | - | -6.0% | -64.6% | -44.5% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 2.42 | 2.68 | 2.85 | 2.02 | 3.98 | 4.01 | 5.15 | 5.39 | 5.54 | 3.58 |
| Quick ratio | 2.42 | 2.68 | 2.85 | 2.02 | 3.98 | 4.01 | 5.15 | 5.39 | 5.54 | 3.58 |
| Cash ratio | 1.33 | 1.25 | 1.44 | 0.58 | 2.58 | 2.66 | 2.85 | 3.15 | 4.67 | 2.89 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | -19.15 | 8.07 | 4.48 | -15.36 | 8.55 | 4.02 | 3.17 | 3.36 | 2.81 | 1.40 |
| Liabilities / Assets | 1.05 | 0.88 | 0.78 | 1.07 | 0.88 | 0.75 | 0.68 | 0.70 | 0.64 | 0.28 |
| Efficiency | ||||||||||
| Asset turnover | 0.14 | - | 0.10 | 0.12 | 0.05 | - | 0.18 | 0.04 | 0.03 | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | 327d | - | 287d | 270d | 206d | - | 66d | 236d | 268d | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | 489d | - | 431d | - | - | - | 518d | 523d | 1677d | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | 13.4x | - | - | - | - | - | - | - |
| P / S | 22.1x | - | 29.9x | 30.0x | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 182.3% | - | -40.5% | 150.5% | 17.6% | - | 393.0% | -53.9% | -65.8% | - |
| Revenue CAGR (3y) | 4.3% | - | 9.8% | 13.6% | -91.5% | - | 41.4% | -25.6% | -10.1% | - |
| Revenue CAGR (5y) | 19.3% | - | 22.8% | 13.0% | 4.5% | - | 49.4% | 19.1% | 12.7% | - |
| Gross profit growth (YoY) | - | - | -91.0% | - | - | - | 436.3% | 89.8% | -24.1% | - |
| Operating income growth (YoY) | 5.0% | - | -850.3% | 15.3% | 5.8% | - | 88.2% | 10.8% | -3.7% | - |
| Net income growth (YoY) | 3.6% | - | -871.2% | 12.3% | -0.9% | - | 87.4% | 5.0% | -110.1% | - |
| EPS growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | - | -50.1% | -23.6% | - | -79.5% | -58.0% | -55.4% | -64.7% | -58.2% | -47.0% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Product / service
$3.09M totalGrant$1.86M · 60.1%
Research And Development$967.3K · 31.3%
License$265.0K · 8.6%
Geographic
$1.03M totalNon Us$1.03M · 100.0%
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing DYADIC INTERNATIONAL INC against the 5 most active filers in the same SIC group.